References
- Leoni LM. Bendamustine: rescue of an effective antineo plastic agent from the mid-twentieth century. Semin Hematol 2011;48 (Suppl. 1):S4–S11.
- Lissitchkov T, Arnaudov G, Peytchev D, . Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132:99–104.
- Kahl BS, Bartlett NL, Leonard JP, . Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106–114.
- Warsch S, Hosein PJ, Maeda LS, . A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 2012;53:1299–1305.
- Robinson KS, Williams ME, van der Jagt RH, . Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
- Fisher RI, Bernstein SH, Kahl BS, . Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
- Inwards DJ, Fishkin PA, Hillman DW, . Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113:108–116.
- Rummel MJ, Niederle N, Maschmeyer G, . Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114 (Suppl. 1): Abstract 405.
- Temsirolimus, bendamustine and rituximab for relapsed follicular lymphoma or mantle cell lymphoma (NCT01078142). Bethesda, MD:National Institutes of Health; 2011. Available from: http://clinicaltrials.gov
- Jerkeman M, Kolstad A, Laurell A, . Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MLC4 (LENA-BERIT) Trial. Blood 2011;118(Suppl. 1): Abstract 2700.
- Magni M, di Nicola M, Carlo-Stella C, . Safety, tolerability, and activity of ofatumumab, bendamustine, and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study. Blood 2011;118(Suppl. 1): Abstract 1647.
- Kahl B, Byrd JC, Flinn IW, . Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.
- Wang L, Martin P, Blum KA, . The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 2011;118(Suppl. 1): Abstract 442.